Catabasis Pharmaceuticals, Inc. (CATB)
| Market Cap | 43.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.30M |
| Shares Out | 23.42M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $1.86 |
| Previous Close | $1.96 |
| Change ($) | -0.10 |
| Change (%) | -5.10% |
| Day's Open | 1.98 |
| Day's Range | 1.84 - 2.00 |
| Day's Volume | 314,517 |
| 52-Week Range | 1.25 - 8.59 |
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today appear...
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investo...
There are some investors who buy stocks that are trading below their liquidation value because they believe they can make remarkable gains out of their investments after the market has reassessed the sh...
Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting ...
Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Catabasis: Worth A Look Ahead Of Phase III Data
Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript
Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study.
Catabasis Pharmaceuticals (CATB) CEO, Jill Milne on Q2 2019 Results - Earnings Call Transcript
Catabasis enrollment is moving fast, having completed enrollment in certain countries, and is on track to report results from the phase 3 PolarisDMD study by second half of 2020.
Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q1 2019 Results - Earnings Call Transcript
Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript
Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.
About CATB
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
| Industry Biotechnology | IPO Date Jun 25, 2015 |
| Stock Exchange NASDAQ | Ticker Symbol CATB |